Paul B. Manning Increases Stake in Candel Therapeutics to 7.9% via Schedule 13D/A Amendment

This Schedule 13D/A amendment filed on March 18, 2026, discloses that Paul B. Manning and related entities have increased their beneficial ownership in Candel Therapeutics, Inc. to 7.9% of the outstanding common stock. The reporting persons collectively own 5,790,999 shares through three entities: Paul and Diane Manning (joint ownership), The Paul B. Manning Revocable Trust, and BKB Growth Investments, LLC. The filing details recent purchases including the Trust's acquisition of 550,458 shares at $5.45 per share on February 23, 2026, as part of an underwritten offering. The amendment updates ownership percentages based on 73,244,473 shares outstanding as of February 20, 2026. Mr. Manning has sole voting and dispositive power over 4,487,247 shares and shared power over 1,303,752 shares. The filing represents continued investment in the biotechnology company by the Manning family and related entities.